These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395 [TBL] [Abstract][Full Text] [Related]
3. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Fields RC; Shimizu K; Mulé JJ Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9482-7. PubMed ID: 9689106 [TBL] [Abstract][Full Text] [Related]
4. Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. Lambert LA; Gibson GR; Maloney M; Barth RJ J Immunother; 2001; 24(3):232-6. PubMed ID: 11394500 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related]
6. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Kreiter S; Selmi A; Diken M; Koslowski M; Britten CM; Huber C; Türeci O; Sahin U Cancer Res; 2010 Nov; 70(22):9031-40. PubMed ID: 21045153 [TBL] [Abstract][Full Text] [Related]
7. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents. Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033 [TBL] [Abstract][Full Text] [Related]
8. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200 [TBL] [Abstract][Full Text] [Related]
9. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]
10. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity]. You J; Wang CL; Hao XS Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273 [TBL] [Abstract][Full Text] [Related]
11. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. DeMatos P; Abdel-Wahab Z; Vervaert C; Seigler HF Cell Immunol; 1998 Apr; 185(1):65-74. PubMed ID: 9636684 [TBL] [Abstract][Full Text] [Related]
13. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells. Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530 [TBL] [Abstract][Full Text] [Related]
14. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
15. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330 [TBL] [Abstract][Full Text] [Related]
16. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767 [TBL] [Abstract][Full Text] [Related]
17. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously. Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973 [TBL] [Abstract][Full Text] [Related]
18. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells. Kawahara M; Takaku H Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871 [TBL] [Abstract][Full Text] [Related]
19. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. Gatza E; Okada CY J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241 [TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]